Ardelyx Maintains 2026 Outlook, Sets $1 Billion Revenue Target for IBSRELA by 2029

Ardelyx has reiterated its financial guidance for 2026, signaling management's confidence in the company's current operational trajectory and strategic execution. The confirmation provides a baseline of stability for investors monitoring the firm's mid-term fiscal health. A primary driver of the company's long-term valuation is the commercial scaling of IBSRELA. Management has established a target of $1 billion in revenue for the drug by 2029, reflecting an aggressive growth strategy and a belief in strong market penetration and therapeutic demand. Beyond commercial goals, Ardelyx continues to advance its clinical development pipeline. The company reported that enrollment for the ACCEL CIC Phase III trial is progressing steadily and is expected to be completed by the end of the current year. From a market perspective, while the reiteration of guidance prevents immediate volatility, the 2029 revenue target provides a high-growth narrative. The successful completion of the Phase III enrollment will serve as the next critical catalyst for the company's clinical valuation.